Clinical Trial Update: Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating sequential PD-1/PD-L1 inhibition followed by LENvatinib in transitional cell tumor and hepatoblastoma after chemotherapy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatoblastoma
• Transitional Cell Tumor

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1/PD-L1 inhibitor sequence

Snippet

Sponsor: RenJi Hospital | Conditions: Transitional Cell Tumor, Hepatoblastoma | Phase 2, Phase 3 | Status: UNKNOWN